NEXT-GENERATION SEQUENCING IDENTIFIES A HOMOZYGOUS NONSENSE P.TYR370* MUTATION OF THE *TMC6* GENE IN A MEXICAN PEDIGREE WITH EPIDERMODYSPLASIA VERRUCIFORMIS

SAMANTHA LÓPEZ-RAMÍREZ¹, YURITZI SANTILLÁN-HERNÁNDEZ¹, EUGENIO CARRASCO-GERARD²,
AGUSTÍN RODAS-SERRANO³, AND JUAN C. ZENTENO^{4,5*}

¹Genetics Program, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM) and Centro Médico Nacional "20 de Noviembre" (ISSSTE), Mexico City; ² Dermatology Program, Faculty of Medicine, UNAM and Hospital General de México "Dr. Eduardo Liceaga", Mexico City; ³Genetics and Molecular Biology Service, Mount Sinai Hospital, Cuenca, Ecuador; ⁴Department of Genetics-Research Unit, Institute of Ophthalmology "Conde de Valenciana", Mexico City; ⁵Department of Biochemistry, Faculty of Medicine, UNAM, Mexico City, Mexico

BACKGROUND

Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by abnormal susceptibility to infection with b-genotype human papillomavirus (HPV) and a particular propensity to develop cutaneous malignancies. Clinical manifestations include flat, scaly, reddish hypo- and hyperpigmented macules, verruca-like papillomatous lesions, seborrheic keratosis-like lesions, and pink-red pityriasis versicolor-like lesions¹. EV patients develop non-melanoma skin cancers on areas of ultraviolet-exposed skin, mostly squamous-cell carcinomas, during the fourth or fifth decade of life. The increased carcinogenesis risk is probably caused by HPV infection, particularly high-risk HPV types 5 and 8².

EV arises most commonly (60-75% of cases) from recessive mutations in either *TMC6* or *TMC8*, two

closely related genes encoding integral membrane proteins that localize to the endoplasmic reticulum and are predicted to form transmembrane channels. *TMC6* is expressed in keratinocytes, in which they control the intracellular levels of zinc³. In addition, at least other ten genes have been associated with the uncommon atypical EV form³. Here, we present the clinical and genetic features of two related EV patients in whom a causal *TMC6* mutation was readily demonstrated by massive DNA sequencing.

METHODS

The proband (patient #1) is a 44-year-old woman who was born in a small village in southern Mexico (~2600 inhabitants). She presented with a generalized dermatosis affecting frontal, temporal and scalp regions, neck, shoulders, chest, back, arms, and thighs.

*Corresponding author:

Juan C. Zenteno

E-mail: jczenteno@institutoodeoftalmologia.org

Received for publication: 18-08-2020

Approved for publication: 26-10-2020

DOI: 10.24875/RIC.20000415

Figure #1. Partial Sanger sequencing of exon 10 of the *TMC6* gene. A homozygous C > G transversion at nucleotide 1110 was demonstrated in DNA from patient #1 (A). This variant predicts a non-sense p.Tyr370* substitution at the EVER1 protein. Genetic analysis demonstrated heterozygosity for the mutation in the healthy father (carrier) of patient #2 (B).

Skin lesions were warty, non-pruritic, hyperkeratotic, and mostly reddish-brown (Supplemental Fig. 1S, A-C). Skin lesions appeared at the age of 7 years. She had a history of parental consanguinity and at least other five living relatives were reported as affected but not available for examination. She developed skin neoplasias (squamous and basal cell carcinoma) which were treated with surgery and radiotherapy. The patient #2 (Supplemental Fig. D-F), a cousin of patient #1, is a 45-year-old male who began his current condition at 7 years of age, presenting flat wart skin lesions distributed throughout the body, predominantly in areas with sun exposure, as well as macules and achromic plaques, mainly on the back and extremities. He began his assessment at the age of 11 years when he underwent his first resection of squamous cell carcinoma.

Given the association of EV to at least 13 genes, the genetic diagnosis was performed using next-generation sequencing (NGS) approach. Genomic DNA was isolated from blood leukocytes using standard procedures. NGS of 4813 genes associated with Mendelian genetic diseases was performed in proband's DNA using the TruSight One system (Illumina Inc., San Diego, CA, USA), employing the Miseq platform (Illumina Inc.). The downstream variant analysis was done with VariantStudio software (Illumina).

RESULTS

After NGS data analysis, a homozygous c.110C > G transversion at exon 10 of the *TMC6* gene was

identified in DNA of the patient #1 (Fig. #1A). This variant is predicted to result in a non-sense p.Tyr370* change at the protein level. The variant was confirmed by Sanger sequencing in DNA from patients #1 and #2. This variant was classified as pathogenic according to the ACMG criteria. As expected, Sanger sequencing revealed that parents of the patient #2 were heterozygous carriers for the p.Tyr370* mutation (Fig. #1B). No DNA samples from other relatives were available for genetic analysis.

DISCUSSION

To the best of our knowledge, this is the first report of molecularly diagnosed EV patients from Mexico and Latin America. NGS readily identified a homozygous mutation, c.1110C > G; p.Tyr370*, in the *TMC6* gene. Interestingly, an identical pathogenic variant in *TMC6* was very recently demonstrated in an EV family of French ancestry³, which corresponded to family 3 in an early clinical report by Lutzner et al.⁴ As no history of European ancestors was recorded in the present family, it is possible that the p.Tyr370* mutation arose independently in these two pedigrees.

While approximately 500 EV cases have been described to date, it is likely that the disease is underdiagnosed due to inadequate clinical suspicion. In Mexico, there are few cases of patients reported with an EV diagnosis⁵ although no molecular diagnosis has been performed in any of them. While it has been stated that mutations in *TMC6* and *TMC8* account

for as many as 60% of EV cases³, the true prevalence of EV-causing mutations is not known due to possible underreporting of mutation-negative cases and to the lack of large cohorts of molecularly analyzed patients. The potential identification of recurrent or founder mutations in a specific population is important because testing for one or a few prevalent mutations is more efficient and low-cost than testing for many rare variants.

SUPPLEMENTARY DATA

Supplementary data are available at Revista de Investigación Clínica online (www.clinicalandtranslational-investigation.com). These data are provided by the corresponding author and published online for the

benefit of the reader. The contents of supplementary data are the sole responsibility of the authors.

REFERENCES

1. Huang S, Wu JH, Lewis DJ, Rady PL, Tying SK. A novel approach to the classification of epidermodysplasia verruciformis. *Int J Dermatol*. 2018;57:1344-50.
2. de Jong SJ, Imahorn E, Itin P, Uitto J, Orth G, Jouanguy E, et al. Epidermodysplasia verruciformis: inborn errors of immunity to human beta-papillomaviruses. *Front Microbiol*. 2018;9:1222.
3. Youssefian L, Vahidnezhad H, Mahmoudi H, Saeidian AH, Daneshpazhooh M, et al. Epidermodysplasia verruciformis: genetic heterogeneity and EVER1 and EVER2 mutations revealed by genome-wide analysis. *J Invest Dermatol*. 2019; 139:241-4.
4. Lutzner MA, Blanchet-Bardon C, Orth G. Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. *J Invest Dermatol*. 1984;83:18-25.
5. Ponce OR, Peniche RJ, Tirado SA, Arellano MI, Peniche CA, León DG, et al. Epidermodysplasia verruciforme. Modelo de carcinogénesis viral. *Dermatol Rev Mex*. 2006;50:83-6.